Destiny Pharma initiates research to explore XF drug potential for CF - Seite 2

 

The work investigating the utility of XF-73 against MRSA in CF follows on from recent peer-reviewed publications demonstrating that XF-73 has superior activity compared to mupirocin against MRSA isolates in a superficial skin infection model3; and that XF-73 has activity against 840 MRSA clinical isolates from patient infections from around the world4. Further data on the ability of XF-73 to prevent bacterial invasion of the bloodstream by MRSA in an in vivo burn wound model is to be presented at this year’s Infection Prevention Society Conference.

 

Dr Bill Love, Chief Scientific Officer of Destiny Pharma, said: "We are excited to initiate this vital research and have high hopes of demonstrating potentially useful activity of XF-73 given our recent publication of activity against hundreds of MRSA strains4 and activity against bacteria within biofilms5. The challenge here will be to explore our drug activity in the presence of mucus which forms a major barrier, causing antibiotic treatment failure."

 

References:

1. Cystic Fibrosis Foundation, 2024. https://www.cff.org/intro-cf/about-cystic-fibrosis
2. Guo et al. (2022). Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 21:456-462
3. Zhang C, Li J, Lu R, Wang S, Fu Z, Yao Z., 2023. Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection Models. Infect Drug Resist. 2023 Jul 25;16:4867-4879. doi: 10.2147/IDR.S417231. PMID: 37520450.
4. Rhys-Williams W, Galvin HM, Love WG., 2023. Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates. Front Cell Infect Microbiol. 2023 Oct 11;13:1264456. doi: 10.3389/fcimb.2023.1264456. PMID: 37900306.
5. Ooi N, Miller K, Randall C, Rhys-Williams W, Love W, Chopra I., 2010. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J Antimicrob Chemother. 2010 Jan;65(1):72-8. doi: 10.1093/jac/dkp409. PMID: 19889790.